What Does ABPI Have To Say About NICE Proposals?

Catchpole welcomes the concept put forth in these new NICE proposals on value based assessment criteria, but says it’s too early to understand the full impact they will have on future medicines access. Read more here. (Source: FirstWord Pharma, 1/10/14).

You might also be interested in:

CVS Caremark's Foray into Cost-Effectiveness Analysis Raises… September 25, 2018
NICE Post Reflects on Partnership with CMAC September 18, 2019
Time to Market: Accelerating Market Access January 4, 2019
Transitioning Payment Models: Fee-for-Service to Value-Based Care November 16, 2018
Orphan Drugs: European Payer Perspectives October 14, 2018
Real World Data Capabilities: Benchmarking Pharma Companies October 30, 2018
APM Warns Against Drug Pricing Proposals January 23, 2019